New cancer clinical trial: Phase 3 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer

Published on: July 26, 2018 at 12:00PM
Condition:   Differentiated Thyroid Cancer
Interventions:   Drug: Donafenib;   Drug: Placebo
Sponsor:   Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Recruiting
https://ift.tt/2K0irj5